Abiopharma

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

New Form 8-K - Dyne Therapeutics, Inc. Filed: 2025-06-30 AccNo: 0001193125-25-152652 Size: 743 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 9.01: Financial Statements and Exhibits

New Form 8-K - Spectral AI, Inc. Filed: 2025-06-30 AccNo: 0001213900-25-059623 Size: 262 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

HCA Healthcare - HCA Healthcare, Inc. 2nd Quarter 2025 Earnings Conference Call

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

HCA Healthcare, Inc. 2nd Quarter 2025 Earnings Conference Call

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

New Form 144 - Zai Lab Ltd Filed: 2025-06-30 AccNo: 0001959173-25-004347 Size: 9 KB

New Form 8-K - RETRACTABLE TECHNOLOGIES INC Filed: 2025-06-30 AccNo: 0001104659-25-064042 Size: 197 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

New Form 10-Q - One World Products, Inc. Filed: 2025-06-30 AccNo: 0001641172-25-017097 Size: 5 MB